Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Shareholder Meeting (November 2026)
22 slides from Lumos Diagnostics's shareholder meeting presentation, Nov 13, 2026
Slide 1: Annual General Meeting – CEO Presentation: FY26 Review and U.S. Commercial Update
rsonal use only Lumos Diagnostics Holdings Limited Annual General Meeting – CEO Presentation FY26 Review and U.S. Commercial Update 13 November 2026 lumosdiagnostics.com 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of rsonal use only (
Slide 3: Board of Directors
Board of Directors rsonal use only Sam Lanyon Doug Ward Catherine Robson Bronwyn Le Grice Aizaz Syed Non-Executive CEO and Non-Executive Non-Executive Non-Executive Chair Managing Director Director Director Director © Lumos Diagnostics . All rights reserved. 3
Slide 4: Lumos develops, manufactures and distributes innovative diagnostic products
rsonal use only Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care. Improving the practice of medicine. © Lumos Diagnostics , all rights reserved 4
Slide 5: Lumos Business Overview
Lumos Business Overview rsonal use only PRODUCTS COMMERCIAL SERVICES FebriDx® Other Products Development Contract Manufacturing People and Capability drive value - able to leverage R&D, IP, manufacturing scale, medical, quality and regulatory skillset across Lumos’ Products and Commercial Services b
Slide 6: FebriDx at a Glance
FebriDx® at a Glance A UNIQUE POINT-OF-CARE TEST TO SUPPORT ANTIBIOTIC TREATMENT DECISIONS rsonal use only FebriDx® helps clinicians, together with other clinical findings, rapidly differentiate a bacterial from a non-bacterial acute respiratory infection after 10 minutes, in patients aged 12 to 64
Slide 7: Company Snapshot
Company Snapshot ASX: LDX · MARKET DATA AS AT 11 NOVEMBER 2026 · SHARE PRICE AND EXECUTION MILESTONES CAPITAL STRUCTURE A$0.40 rsonal use only A$0.35 3 Shares on issue 988.2m Options – investors 60.4m A$0.30 Options & performance rights – employees 61.2m A$0.25 2 Borrowings Nil A$0.20 A$0.15 1 5 MAR
Slide 8: FY26 and Year-to-Date Highlights
FY26 and Year-to-Date Highlights REGULATORY, REIMBURSEMENT, DISTRIBUTION, ADOPTION AND BALANCE SHEET rsonal use only 01 02 03 04 05 >US$1bn US$41.38 US$317m 365 US$11.8m U.S. TAM per annum Medicare rate per test minimum contracted value U.S. sites in implementation cash, no debt FDA CLIA waiver Reim
Slide 9: Financials Summary - Annual
Financials Summary - Annual Revenue (US$M) Gross Profit (US$M) & Margin Adjusted EBITDA (US$M)1 rsonal use only 14.0 $13.2 10.0 100%0.0 $12.4 12.0 $11.1 $7.8 $7.9 FY23 FY24 FY25 FY26 $10.5 8.0 $7.1 80% -1.0 10.0 $6.0 8.0 6.0 60% -2.0 64.0% 62.9% 57.1% 60.1% 6.0 4.0 40% -3.0 -$2.8 4.0 -$3.4 2.0 20% -
Slide 10: FY27 Year to Date at a Glance
FY27 Year to Date at a Glance QUARTER ENDED 30 SEPTEMBER 2026 AND UPDATES TO 9 NOVEMBER 2026 rsonal use only 365 495 13 +224% US$11.8m U.S. sites on implementation sites in evaluation Top 100 groups product revenue cash, no debt Including WellStreet expansion to 141 Pipeline at 9 Nov 2026, after 97
Slide 11: FebriDx Opportunity, Commercial Strategy and Traction
rsonal use only FebriDx Opportunity, Commercial Strategy and Traction
Slide 12: Why the Respiratory Season Matters for FebriDx
Why the Respiratory Season Matters for FebriDx® THE SEASON BRINGS MORE PATIENTS AND MORE ANTIBIOTIC DECISIONS, AND MOST ARE NOT FLU rsonal use only 1 WHEN: THE SEASON BRINGS THE PATIENTS GETTING IN POSITION FOR THE SURGE Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun 365 U.S. sites on implementatio
Slide 13: WellStreet Shows How FebriDx Scales
WellStreet Shows How FebriDx® Scales 6TH LARGEST U.S. URGENT CARE NETWORK · PILOT → VALIDATE → PROTOCOL → NETWORK rsonal use only 1 44 141 200+ pilot site locations locations locations anticipated October 2025, Atlanta (Piedmont JV) April 2026, after CLIA waiver November 2026: Ohio, Georgia, Michiga
Slide 14: Where We Focus: The Top Urgent Care Networks
Where We Focus: The Top 100 Urgent Care Networks ONE NETWORK DECISION CAN MOVE MANY SITES · WELLSTREET IS ONE OF THE TOP 100 rsonal use only FROM THE MARKET TO OUR FOCUS WHY THE TOP 100 FIRST U.S. urgent care and primary care sites¹ One decision, many sites ~174,000 ~68m ARI visits a year across the
Slide 15: Our FY27 Story: Awareness, Validation, Go-Live
Our FY27 Story: Awareness, Validation, Go-Live HOW LUMOS IS TURNING CLIA WAIVER INTO PROTOCOL -DRIVEN, RECURRING USE OF FEBRIDX® rsonal use only 01 BUILD AWARENESS 02 VALIDATE 03 LIVE Put FebriDx® in front of decision-makers at the Top Accounts prove clinical and economic value in their FebriDx® emb
Slide 16: We Have Delivered What We Said on Sites
We Have Delivered What We Said on Sites U.S. SITES ON IMPLEMENTATION UP FROM 170 TO 365 SINCE 26 JULY 2026 · 495 SITES IN EVALUATION rsonal use only FEBRIDX® SITES BY STAGE STATED VS DELIVERED Live / on implementation Sites in evaluation (pipeline) 14 APR 2026 Delivered We said: WellStreet to launch
Slide 17: Paediatric Study Update
Paediatric Study Update BARDA-FUNDED U.S. STUDY IN CHILDREN AGED 2 –12 · CURRENT 12–64 CLIA-WAIVED COMMERCIALISATION IS UNAFFECTED rsonal use only ~400 +3 US$2.6m 15%–20% patients enrolled hospital EDs in Q2 FY27 BARDA funding received potential U.S. market expansion Up from 250 at Milestone 7 in Ma
Slide 18: FebriDx is manufactured in Carlsbad, California
FebriDx® is manufactured in Carlsbad, California VERTICALLY INTEGRATED MANUFACTURING · ISO 13485 CERTIFIED · NEW FACILITY SCHEDULED FOR END CY2026 FebriDx® is manufactured in-house, not outsourced. Every test is rsonal use only made by Lumos in Carlsbad, CA. 60%+ 10m ISO 13485 PRODUCT GROSS MARGIN T
Slide 19: FY27 Priorities
rsonal use only FY27 Priorities
Slide 20: FY27 Priorities
FY27 Priorities BUILDING MARKET AWARENESS IS NOW THE FIRST PRIORITY · EACH STEP FEEDS PIPELINE CONVERSION AND UTILISATION PRIORITY FY27 FOCUS rsonal use only WHAT WE WILL REPORT ON • Live sites and states covered 01 Build market awareness Execute the marketing plan to drive awareness and grow the pi
Slide 21: Near-Term Catalysts to Watch
Near-Term Catalysts to Watch MILESTONES OVER THE NEXT SIX MONTHS · ALL PREVIOUSLY DISCLOSED CATALYST TIMING AND WHAT TO WATCH rsonal use only HOW WE WILL UPDATE THE MARKET • Material account decisions by ASX announcement 01 WellStreet network rollout From 141 to all 200+ locations, anticipated by 31
Slide 22: Thank You
rsonal use only Thank You Lumos Diagnostics Holdings Limited | ASX: LDX ir@lumosdiagnostics.com · lumosdiagnostics.com This presentation contains forward-looking statements. Past performance is not necessarily indicative of future results. lumosdiagnostics.com
Lumos Diagnostics Holdings — Shareholder Meeting (November 2026) on 6ix